News
Novo Nordisk's European stocks fell over 4% as the company's third-quarter performance was below expectations, and it lowered its full-year sales growth forecast
Source: Wallstreetcn The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments